R&D investment of selected Chinese listed biotechnology companies 2017-2019
In 2019, the Nasdaq listed Beigene spent approximately 6.5 billion U.S. dollars on research and development. Beigene is one of the largest biotechnology companies in China, with a market cap of nearly 34 billion U.S. dollars as of February 2021.